Cosmo Bio Co

Cosmo Bio Co ROCE

The Return on Capital Employed (ROCE) of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 3.43 %. In the previous year, Return on Capital Employed (ROCE) was 3.33 % — a change of 3.22% (higher).

ROCE

3.43 %

YoY

3.22%

Last updated:

In 2025, Cosmo Bio Co's return on capital employed (ROCE) was 3.43 %, a 3.22% increase from the 3.33 % ROCE in the previous year.

The Cosmo Bio Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
4.66 JPY
Jan 1, 2019
5.54 JPY
Jan 1, 2020
9.56 JPY
Jan 1, 2021
12.59 JPY
Jan 1, 2022
9.47 JPY
Jan 1, 2023
5.75 JPY
Jan 1, 2024
3.33 JPY
Jan 1, 2025
3.43 JPY
The Cosmo Bio Co ROCE history
YEARROCEYoY
3.43 %+3.22%
3.33 %-42.12%
5.75 %-39.27%
9.47 %-24.83%
12.59 %+31.69%
9.56 %+72.50%
5.54 %+18.89%
4.66 %+64.40%
2.84 %-57.37%
6.65 %+111.09%
3.15 %+26.29%
2.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Cosmo Bio Co's Return on Capital Employed (ROCE)

Cosmo Bio Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Cosmo Bio Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Cosmo Bio Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Cosmo Bio Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Cosmo Bio Co stock

Return on Capital Employed (ROCE) of Cosmo Bio Co is 3.43 % in 2025.

Return on Capital Employed (ROCE) of Cosmo Bio Co changed from 3.33 % to 3.43 %, representing a 3.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Cosmo Bio Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Cosmo Bio Co